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Renal antigens in mercuric chloride induced, anti-GBM autoantibody
glomerular disease. Two antibody probes were used to characterize the
putative renal antigens of HgCI2-induced antiglomerular basement
membrane renal disease in Brown Norway (BN) rat. The first probe was
the linear immunofluorescence imparting, in vivo bound, nephritogenic
antiglomerular-basement-membrane autoantibody (anti-GBM-Ab). The
second probe was a rat monoclonal antibody to the B subunit of laminin
that was obtained from fusion of spleen cells of HgCI2 injected BN rat.
By enzyme-linked immunosorbent assay (ELISA) the anti-GBM-Ab
reacted with laminin, type LV collagen, collagenase-resistant noncollag-
enous portion of glomerular basement membrane (GBM), saline soluble
proteins of kidney cortex homogenate and fibronectin. Western blot
analysis of laminin indicated that the reactive epitopes detected by both
probes were on the B chain subunit but not the A subunit. In
nonreduced collagenase-digested GBM the epitopes were present on 27
kD and 42 to 48 kD polypeptides. A similar pattern was seen on
collagenase-digested human GBM. On rat and human GBM the patterns
obtained with rat autoantibody and autoantibody from a patient with
Goodpasture syndrome were similar, suggesting that some of the in
vivo bound anti-GBM autoantibodies in HgCl2-induced disease in rat
are directed against epitopes which are similar to the Goodpasture
antigen of human. Reactive epitopes were also detected on saline
soluble proteins of kidney cortex homogenate with the predominant
antigen being a 31 kD polypeptide. In the saline soluble proteins the
reactive polypeptides including the major 31 kD polypeptide did not
originate from laminin, type IV collagen, or the collagenase-resistant
noncollagenous part of GBM. The precise structural origin of soluble
proteins was not defined. The epitopes in type IV collagen and
fibronectin could not be further characterized for molecular mass by
Western blot analysis.
Administration of mercuric chloride (HgCI2) to Brown Nor-
way (BN) rat results in the induction of autoantibodies to
glomerular basement membrane (GBM) and a biphasic glomer-
ulonephritis. The first phase is characterized by linear and the
second phase by granular immunofluorescence along the GBM
U]. The linear immunofluorescence is due to the binding of
anti-GBM antibodies [1]. The knowledge of the physicochemi-
cal nature of the antigens (epitopes) in GBM to which the
elicited antibodies bind in vivo to produce the anti-GBM
antibody-induced glomerular disease is limited. Although anti-
bodies to laminin and pro-collagen IV and possibly to fi-
bronectin were detected earlier in the serum of an occasional
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animal by Bellon et al [2], only recently while our studies were
in progress, Fukatsu et at [31 have demonstrated that the in vivo
bound antibodies when tested by ELISA react with type IV
collagen and laminin. The purpose of this study was to obtain
information regarding the physicochemical characteristics of
these reactive proteins and other yet unidentified renal anti-
gens. Autoantibodies eluted from the glomeruli of diseased
animals and a rat monoclonat antibody obtained from fusion of
spleen cells of a HgCI2 injected BN rat were used as the specific
probes to obtain this information.
Methods
Materials
Male BN rats, weighing 150 to 170 g were obtained from
Harlan, Inc. (Indianapolis, Indiana, USA) Tissue Tek OCT
Compound, normal rat IgG and anti-rat IgG were obtained from
Miles Labs, Inc. (Naperville, Illinois, USA). Fluorescein iso-
thiocyanate (FITC)-labelled F(ab)2 goat anti-rat IgG (hain
specific) and horseradish peroxidase (HRPO) labelled goat-
anti-rat IgG were obtained from Cappel Lab Inc., (Cochran-
ville, Pennsylvania, USA).
Nunc Immune I polystyrene plates used for ELISA were
obtained from Intermed (Thousand Oaks, California, USA). All
reagents for sodium dodecyl sulfate polyacrylamide gel electro-
phoresis (SDS-PAGE) were obtained from Bio-Rad Labs (Rich-
mond, California, USA). Nitrocellulose membranes (BA-85) for
Western blots were obtained from Schleichter & Schuell, Inc.
(Keene, New Hampshire, USA). Stainless mesh sieves were
obtained from Arthur H. Thomas & Co. (Philadelphia, Penn-
sylvania, USA). Laminin, fibronectin and type IV collagenase
and other chemicals were obtained from Sigma Chemicals, St.
Louis, Missouri, USA. Laminin was prepared from mouse
Engelbreth-Holm-Swarm (EHS) tumor and fibronectin from rat
plasma by the supplier. Laminin was also obtained from Col-
laborative Research Inc. (Bedford, Massachusetts, USA) and
had been obtained by the supplier from EHS mouse tumor.
Anti-rat Vectastain ABC (avidin-biotin-complex) immunoper-
oxidase kit was obtained from Vector Labs, Burlingame, Cali-
fornia, USA. Native type IV collagen was obtained from
Collaborative Research Inc., Bedford, Massachusetts, USA. It
had been purified without pepsin extraction from EHS mouse
tumor by the supplier.
Induction of anti-GBM Ab disease
BN rats were injected subcutaneously three times a week on
alternate days for two weeks with 0.1 mgIlOO g body weight
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with mercuric chloride dissolved in distilled water as I mg/mi
solution. Control rats were injected with distilled water only.
Rats were sacrificed on day 16 and their kidneys processed for
direct immunofluorescence and for eiution of in vivo bound
antibodies. Day 16 was chosen for sacrificing to avoid the
development of the second phase of glomerular disease (mem-
branous glomerulopathy).
Immunofluorescence method
Methods for direct and indirect immunofluorescence have
been described in detail earlier [41. The first antibodies were the
anti-GBM antibody obtained from giomeruli of diseased BN
rats and the rat monoclonal antibody to laminin B subunit. The
second antibody was FITC labelled F(ab)2 goat anti-rat IgG.
Appropriate controls, including staining of sections with FITC
labelled F(ab)2 goat anti-rat IgG only, absence of first antibody
(eluates from normal kidneys or irrelevant monoclonal anti-
body), and FITC-labelled F(ab)2 goat anti-rat IgG absorbed
with normal rat IgG, were used.
Preparation of antigens
Normal male rats weighing 200 to 300 g were anesthetized
with ether. The kidneys were perfused with phosphate buffered
saline (PBS), pH, 7.4, through the abdominal aorta at physio-
logical pressure (110 mm Hg). The cortex was separated from
the medulla and chopped into a thick paste. The giomeruli were
isolated by the sieving technique. Renal cortex tissue was
passed through a size 60 (250 pm opening) and size 100(150 pm
opening) stainless steel mesh screens placed in series and
collected on size 200 mesh screen (75 j.m opening) by rinsing
with cold PBS. The glomeruli collected from the top of the 200
mesh screen were saved. The suspension passing through the
screens was centrifuged at 4°C at 100,000 x g for one hour. The
supernatant containing water soluble antigens was dialyzed
against distilled water and lyophilized (Fx1B). Over 90 to 95%
of glomeruli obtained were free of Bowman's capsule with
minimal tubular contamination. The isolated glomeruli were
washed once with PBS and twice with distilled H,O by centrif-
ugation in a conical tube at 400 x g at 4°C and lyophilized. For
preparation of GBM the lyophilized glomeruli were suspended
in 1 M NaCI and sonicated in 15 second bursts, with ice cooling,
and examined by light microscopy for disruption. Sonication
was continued until all glomeruli were disrupted (usually 1.5 to
2 mm), The sonicated material was centrifuged at 4°C at 3000 X
g for 10 minutes. The sediment was washed three times with
distilled water by centrifugation at 4°C at 7500 x g and
lyophilized. For digestion with collagenase lyophilized GBM
obtained from 500 mg of lyophilized glomeruli was suspended in
10 ml of 20 mis Tris-HC1 buffer, pH 7.3, containing 5 m CaCl2
and 0.01% sodium azide and reacted with 2.5 mg of collagenase
type IV (Sigma Chemicals) at 37°C overnight on a shaker. It was
centrifuged at 15,000 x g for 30 minutes and the supernatant
dialyzed extensively against PBS. A yield of 1.2 mg protein was
obtained. Protein content of all antigen preparations was deter-
mined by the BCA method (Pierce Biochemicals, Akron, Ohio,
USA). Collagenase-digested human GBM was prepared simi-
larly from a human kidney obtained at autopsy.
Antibodies
Animals were sacrificed on day 16 and their kidneys saved.
Kidneys showing only linear fluorescence along GBM were
pooled. Glomeruli were isolated from these kidneys as de-
scribed above and washed several times by centrifugation at
4°C with PBS, pH 7.4, until the supernatant had negligible
absorbance at 280 nm. The antibody was eluted from glomeruli
by incubating glomeruli in an end to end shaker at room
temperature in 1 M propionic acid for 30 minutes. The glomeruli
were centrifuged at 800 x g at 4°C for 10 minutes and the
supernatant neutralized to, pH 7.4, with 1 M Tris. It was
dialyzed against PBS, pH 7.4, at 4°C and concentrated by
ultrafiltration in an Amicon ultrafiltration apparatus using PM1O
filter (molecular weight cut off 10,000). The protein content of
the eluted antibody was determined by the BCA method and its
tissue specificity tested by indirect immunofluorescence on
normal rat kidney sections. Antibody against the Goodpasture
antigen was the serum of a patient with Goodpasture syndrome.
ELISA procedure
The ELISA was performed in a standard manner according to
the method of Voller, Bidwell and Bartlett [5]. Polystyrene
flat-bottomed microtiter plates were coated with individual
antigens dissolved in 5 m carbonate-bicarbonate buffer, pH
9.6. The first antibody was anti-GBM antibody eluted from
glomeruli of diseased BN rats. The second antibody was HRPO
labelled goat anti-rat IgG. The absorbance was read at 492 nm
in an E1A spectrometer. Controls were: reaction on BSA
coated wells (antigen control), reaction of HRPO labelled
antibody only on antigen coated wells (second antibody control)
and reaction with acid eluates of normal glomeruli on antigen
coated wells (first antibody control). All measurements were
performed in duplicates.
SDS-PAGE and Western blots
Antigens (5 to 200 .tg) were subjected to SDS-PAGE under
non-reducing and reducing conditions (5% mercaptoethanol)
using the discontinuous buffer system of Laemmli [6]. Electro-
phoresed peptides were transblotted to nitrocellulose according
to the method of Towbin, Stahelin and Gordon [7]. The first
antibody was the anti-GBM antibody was eluted from glomeruli
of diseased BN rats. The reaction of the first antibody was
detected using Vectastain ABC immunoperoxidase system kit
according to the instructions from the supplier. Color reaction
was developed by using 0.05% 4-chloro-l-naphthol in 15%
methanol, 0.015% H202 in PBS. Controls of reaction without
first antibody and with acid eluates of normal kidneys (antibody
controls) and reaction on a BSA blot (antigen control) were
included.
Monoclonal antibodies
Monoclonal antibodies were obtained by standard proce-
dures [8] by fusing spleen cells from HgCI2 injected BN rats
with SP2/0 nonsecretor mouse myeloma cells. Hybrids produc-
ing antibodies were screened by indirect immunofluorescence
on normal BN kidney sections. Positive hybrids were single cell
cloned by limiting dilution. Supematants from single cell cloned
hybridomas were used for analyses.
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Fig. 1. Reactivity of anti-GBM autoantibody eluted from glomeruli of
HgCI2 injected Brown Norway (BN) rats. Frozen, unfixed kidney
section from a normal BN rat was reacted with antibody eluted from
glomeruli of BN rats injected with HgCI2 and then studied by indirect
immunofluorescence using fluorescein-labelled anti-rat IgG. Linear
fiorescence can be seen along the glomerular basement membrane
(GBM). Reaction with tubular basement membrane and arterioles is
also seen. Magnification (356x).
Results
All animals (N = 15) developed anti-GBM autoantibody-
induced glomerulonephritis characterized by linear staining for
rat IgG on direct immunofluorescence. Proteinuna measured by
sulfosalicylic acid method ranged from 200 to 432 mg/day
(normal less than 5 mg/day).
Antibody eluted from the glomeruli of diseased animals with
exclusive linear glomerular fluorescence had the following
characteristics: It was IgG (tested by ELISA using isotyping kit
from Zymed Lab, San Francisco, California, USA) and it
stained GBM in a linear pattern by indirect immunofluores-
cence on normal rat kidney section (Fig. 1). The reaction on
GBM could be abolished followed absorption with lyophilized
whole glomeruli. It was reactive by ELISA on microtiter plates
coated with FxlB, collagenase-digested GBM, laminin, and
type IV collagen and fibronectin.
Monoclonal antibody against laminin
A monoclonal antibody was characterized to be reactive
against the B subunit of laminin. On direct immunofluorescence
it appeared to react with the GBM or the adjacent plasma
membrane of visceral glomerular epithelial cells in an inter-
rupted linear pattern. It also reacted with the vessel wall but no
reaction was seen with tubular basement membrane or Bow-
man's Capsule (Fig. 2). The monoclonal antibody was highly
reactive by ELISA on laminin coated microtiter wells and on
Western blot analysis it only reacted with the B subunit and not
the A subunit of laminin (Fig. 8).
ELISA
Laminin, type IV collagen, FX1B, collagenase-digested
GBM and fibronectin coated individually on microtiter plates
Fig. 2. Reactivity of monoclonal antibody to laminin. Frozen, unfixed
kidney section from a BN rat was reacted with monoclonal antibody to
laminin and then studied by indirect immunofluorescence using fluores-
cein-labelled anti-rat IgG. Interrupted linear fiorescence can be seen
along GBM or the adjacent plasma membrane of visceral glomerular
epithelial cells. Magnification (212x).
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Fig. 3. Reactivity of glomeruli-eluted anti-GBM autoantibody from
HgC12 injected Brown Norway rats with various kidney proteins studied
by ELISA. Dose response curves (antibody titration curves) for laminin(0) soluble kidney cortex homogenate proteins (•, FX1B), collage-
nase-digested GBM (0), type IV collagen (x) and fibronectin (A)
against anti.GBM autoantibody (0.025 to 8.5 g/ml of IgG) are shown.
Laminin, type IV collagen and fibronectin were coated on microtiter
wells at a concentration of 5 g/ml and FX113 and collagenase-digested
GBM at 25 g/ml concentration. Optical density values represent
means of duplicates from which control values obtained with acid
eluates of normal SN rat glomeruli have been subtracted.
wells tested positive for antigen reactivity when reacted with
anti-GBM-Ab eluted from glomeruli of diseased animals (Fig.
3). Maximum activity was seen against laminin and least against
fibronectin. Collagenase-digested GBM proteins and soluble
kidney cortex homogenate proteins showed moderate levels of
0.04 0.1 0.4 1.0 4.0
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Fig. 4. Inhibition curves for type IV collagen (X), laminin (D), soluble
kidney cortex homogenate proteins (I, FXIB) and collagenase-di-
gested GBM (0) constructed by ELISA performed on microtiter wells
coated with collagenase-digested GBM. Collagenase-digested GBM
was coated at a concentration of 25 g/m1. Anti-GBM autoantibody was
used at a concentration of 5 sg/ml. The inhibiting proteins, FxIB and
collagenase-digested GBM were used at a concentration of 2 to 640
g/ml, and type IV collagen and laminin at 2 to 64 sgIml. Inhibition was
performed in a standard manner (Methods). Each value represents the
mean of two optical density values from which the control optical
density value has been subtracted. The values are expressed as percent
of maximum binding.
Fig. 5. Inhibition curves for laminin (D), type IV collagen (X), colla-
genase-digested GBM (0), and soluble kidney homogenate proteins (•,
FXJB) constructed by ELISA performed on microtiter wells coated with
FXJB. FX1B was coated at a concentration of 25 g/ml. Binding of
anti-GBM autoantibody (5 jzg/ml) to FXIB was inhibited by laminin (1
to 62 /Lg/ml), collagen type IV (I to 62 g/ml), collagenase-digested
GBM (2 to 440 sgIml) and FXIB (2 to 360 sgIml). The procedure of
inhibition and the way of expression of data are similar to those used in
Figure 4.
activity and small amount of activity was seen against type IV
collagen.
Several inhibition assays were performed. Antigens were
tested as inhibitory antigens against themselves (antigen coated
on plates and used in inhibition are the same) and against the
other antigens (antigen coated on the plates and that used in
inhibition assay are different.) Inhibition was performed in a
standard manner by incubating 50 1d of antibody (5 jig/mI) in
PBS-T and 50 jil of inhibiting antigen at various concentrations
in the antigen coated wells for one hour at 37°C. The binding
inhibition was detected by HRPO-labelled second antibody in
the usual manner as described above. Results are shown in
Antigen. sg/m/
Fig. 6. Inhibition curves for laminin (0), soluble kidney cortex ho-
mogenate proteins, FXIB (•) and collagenase-digested GBM (0)
constructed by ELISA performed on microtiter wells coated with
laminin. Laminin was coated at a concentration of 5 g/ml. Binding of
anti-GBM autoantibody (5 ig/ml) to laminin was inhibited by various
concentrations of collagenase (5 to 700 g/ml) digested GBM, FX1B (3
to 860 g/m1) and laminin (4 to 250 sg/ml). The procedure of inhibition
and the way of expression of data are similar to those used in Figure 4.
Antigen, ag/mI
Fig. 7. Inhibition curves for soluble kidney cortex homogenate (S.
FXIB) and collagenase-digested GBM (0) constructed by ELISA
performed on microtiter wells coated with type IV collagen. Type IV
collagen was coated at a concentration of 5 gIml. Binding of anti-GBM
autoantibody was inhibited by various concentrations of FXIB (3 to 660
tgIml) and collagenase-digested GBM (3 to 860 g/ml). The procedure
for inhibition and the way of expression of data are similar to those used
in Figure 4.
Figures 4 through 7. Figure 4 shows partial inhibition of the
binding of the anti-GBM antibody to collagenase-digested GBM
proteins by FX lB proteins and no inhibition to laminin or type
IV collagen. Figure 5 shows partial inhibition of binding to
FX1B proteins by collagenase-digested GBM proteins and
essentially no inhibition by laminin or type IV collagen. These
results suggest that there is partial sharing of epitopes between
collagenase-digested GBM and FX1B proteins but probably not
between these two proteins and laminin and type IV collagen.
Figure 6 shows only minimal inhibition of antibody binding to
laminin by collagenase-digested GBM proteins and no inhibi-
tion by FX1B proteins. The minimal inhibition seen with
collagenase-digested GBM is probably due to contamination of
collagenase solubilized GBM by laminin present in the whole
GBM preparation. Figure 7 shows partial inhibition of antibody
binding to type IV collagen by collagenase-digested GBM
proteins and minimal inhibition by FX1B proteins. Inhibition
tests with type IV collagen in Figure 6 and with laminin and
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Fig. 8. Western blot analyses of renal antigens. A. Commassie blue
staining pattern and immunoblot of laminin. Lane 1 shows Commassie blue
staining pattern of laminin (20 Lg) separated under reducing conditions in 4
to 8 percent gradient SDS-PAGE gels, Lanes 2, 3, 4 are immunoblots of
laminin prepared from SDS-PAGE gels run under the above conditions.
Strips were reacted with primary antibody or control and the reaction
studied by indirected immunoperotidase technique (Vectastain). Lane 2
shows reaction of anti-GBM autoantibody (5 hg/mI) acid eluted from
glomeruli HgCI2 injected BN rats. Lane 3 shows reaction of a monoclonal
antibody (5 sg/ml) to laminin. Lane 4 is a control reacted with acid elutes of
normal BN rat glomeruli, B. Immunoblot of FxIB antigens. Fx1B antigens
(200 sg) were separated under reducing conditions by SDS-PAGE in 10
percent acrylamide gel. Lane I shows reaction of anti-GBM autoantibody (5
gIml) and lane 2 reaction of control from acid elutes of normal BN
glomeruli. C. Immunoblot of collagenase-digested GBM of rat (Lanes 1 and
2) and human (Lanes 3 and 4) kidney. GBM antigens (30 /.Lg) were separated
under reducing conditions by SDS-PAGE in 10 percent acrylamide gel.
Lanes I and 3 show reaction of anti-GBM autoantibody (5 .Lg/ml) acid
eluted from glomeruli of HgCI2 injected BN rats, and lanes 2 and 4 reaction
of acid elutes of normal BN glomeruli. D. Immunoblot of collagenase-
digested GBM of rat (lanes I to 4) and human (lanes. 5 to 8). GBM antigens
(30 g) were separated under non-reducing conditions by SDS-PAGE on a
10 percent acrylamide gel. Lanes 1 and S were reacted with rat anti-GBM
autoantibody acid eluted from glomeruli of HgCl2 injected BN rats. Lanes 2
and 6 are control blots reacted with acid eluates of normal BN glomeruli.
Lanes 3 and 7 were reacted with serum (1:40 dilution) of a patient with
Goodpasture syndrome. Lanes 4 and 8 are control blots reacted with normal
human serum (1:40 dilution).
type IV collagen in Figure 7 could not be performed because
they interfered in the assay. Apparently this was due to the
binding of laminin to native type IV collagen [9, 10] and the
binding of type IV collagen in solution to type IV collagen on
the plate wall presumably due to aggregation in vitro [11]. This
problem of interference was not seen in assays where collage-
nase-digested GBM protein were coated on plastic wells prob-
ably because laminin does not interact with the carboxy termi-
nal noncollagenous domain (NC!) [10]. It is interesting to note
that inhibition by laminin does not appear very impressive in
Figure 6. This may be due to binding of laminin in solution to
laminin on plastic wall probably because laminin can polymer-
ize and self-assemble in vitro [!2].
Western blots
These results are shown in Figure 8. In laminin resolved
under reducing conditions (Panel A) the reactive epitopes were
detected in the B subunit (200 to 230 kD) polypeptides. No
reaction was detected on the A subunit (420 kD). The faint band
below the B subunit reaction is most likely due to reaction with
contaminating protein in laminin since our monoclonal antibody
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only reacts with the B subunit and not with the contaminating
protein.
In Fx1B (Panel B) 5—6 bands were seen. The most prominent
band was at 31 kD. A less prominent band at 45 kD and three to
four other faint bands varying from 26 kD to 48 kD were also
seen in immunoblots of FxlB. The prominent band at 54 kD
appears to be due to the reaction of anti-rat IgG second
antibody (Vectostain) with the heavy chain of rat IgG present as
a contaminant in FX1B.
In reduced collagenase-digested GBM (Panel C) prominent
bands at 28 kD and at 53 to 58 kD were seen. Bands of similar
molecular weight were also seen when collagenase-digested
human GBM was reacted with the rat autoantibody. No reac-
tion was seen with human Goodpasture autoantibody on rat or
human reduced collagenase-digested GBM.
Comparison of rat autoantibody and Goodpasture autoanti-
body on nonreduced collegenase-digested human and rat GBM
revealed both antibodies to react with monomer (27 kD) and
dimer (42 to 48 kD) polypeptides (Panel D). These results show
that some of the in vivo bound autoantibodies in BN anti-GBM
antibody disease are directed against the rat equivalent of the
Goodpasture antigen of humans. The reaction of Goodpasture
autoantibody with only non-reduced and not reduced polypep-
tides is consistent with earlier reports [13—191. The band near
the top of the gel (150 kD) in lanes 1—4 is due to IgG present in
the collagenase-digested rat GBM which has reacted with the
anti-rat IgG second antibody used in the immunoperoxidase
reaction.
No bands of reactivity with the rat autoantibody could be
seen on type IV collagen or fibronectin blots.
Discussion
Our results show that the in vivo bound anti-GBM autoanti-
bodies that produce linear immunofluorescence in HgCI2 in-
duced autoimmune glomerular disease in BN rat are directed
against epitopes present in laminin, collagenase-resistant
noncollagenous portion of GBM including the rat equivalent of
the Goodpasture antigen of humans, saline soluble proteins of
kidney cortex homogenate, type IV collagen, and fibronectin.
The majority of autoantibodies react with laminin, a minority
reacts with type IV collagen and fibronectin and a significant
amount reacts with collagenase-resistant noncollagenous por-
tion of GBM and saline soluble kidney proteins.
Inhibition studies in ELISA show that there is essentially no
sharing of the reactive epitopes among laminin and the collage-
nase-resistant noncollagenous portion of GBM and saline solu-
ble kidney proteins. However, there is a definite sharing of
some epitopes between collagenase-resistant noncollagenous
proteins of GBM and saline soluble kidney proteins. Whether
some of the reactive epitopes in native type IV collagen are
partially shared by the collagenase-resistant noncollagenous
proteins of GBM is not clear. If they are shared it may be due
to the noncollagenous portion present in native type IV colla-
gen. However, it is also possible that the inhibition observed on
type IV collagen coated plates by collagenase-digested GBM
proteins is due to the incomplete digestion of GBM by collage-
nase and therefore, type IV collagen may be present in the
preparation. The above interpretation is strengthened by the
lack of inhibition shown by type IV collagen on plates coated
with collagenase-digested GBM.
Native laminin is a large (1,000 kD) glycoprotein and is one of
the main components of basement membranes [20]. It is com-
posed of three disulfide-bonded polypeptide chains (B!, B2 and
A) that are folded into a cross-shaped structure consisting of
three 37 mm-long short arms and a single long arm about 77 mm
in length [21, 221. When electrophoresed in SDS-PAGE under
reducing conditions it separates into two distinct bands which
have been referred to as A (440 kD) and B (220 kD) subunits
[20]. Although the entire amino acid sequence of mouse laminin
Bi and B2 chains [23, 24] has been elucidated the complete
structure of laminin remains to be determined. However, it
appears that the SDS-PAGE separated subunit A (440 kD)
represents the long arm of the cross and the three short arms are
represented in B subunit [25].
Our studies of the molecular form of the epitopes in laminin
by Western blot analysis show that the epitopes are present in
the B subunit and not the A subunit. These results were
confirmed by the reaction of a rat monoclonal antibody (ob-
tained from a rat injected with HgCl2) which reacted with B
subunit only. The reaction with B subunit only suggests that
epitopes are probably not present in association with heparan
sulfate proteoglycans because it is the long arm of the A subunit
that is believed to contain the binding sites for heparin and
heparan sulfate proteoglycan [26—28]. This hypothesis is con-
sistent with observations made by Fukatsu et al [3] who while
studying these antibodies by ELISA did not find reaction
against heparan sulfate proteoglycans. Since the epitopes are
present on the B subunit which contains the binding sites for
type IV collagen [10, 25, 27—29] some of the epitopes on laminin
may possibly be formed in association with type IV collagen.
This may explain the small amount of reactivity of the autoanti-
bodies seen with type IV collagen on ELISA. It should be
noted, however, that there is controversy whether the type IV
collagen binding sites are present in B subunit or the long arm
(A subunit) [241.
In the collagenase-resistant noncollagenous portion of GBM
the Western analysis shows that the epitopes under reducing
conditions are detectable on 28 kD and 53 to 58 kD polypeptides
and under nonreducing conditions on 27 kD and 42 to 48 kD
polypeptides, respectively. It is known that in collagenase-
solubilized GBM under nonreducing conditions the Goodpas-
ture autoantibody reacts with 26 to 28 kD (monomer) and 42 to
54 kD (dimers) polypeptides [13—19]. Because in our studies the
Goodpasture autoantibody reacts with similar nonreduced 27
kD and 42 to 48 kD polypeptides on both rat and human GBM
it indicates: I) that Goodpasture-like antigen is present in rat
kidney, and 2) that the nonreduced rat 27 kD polypeptide
represents the monomer and 42 to 48 polypeptides the dimers of
Goodpasture-equivalent of rat antigen. However, there appears
to be some dissimilarity between the human Goodpasture
antigen and the rat equivalent of Goodpasture antigen as
suggested by the broader range of reactivity of Goodpasture
autoantibody seen in the dimeric region of rat GBM versus the
human GBM. Previous studies have shown that the reduced
monomer of Goodpasture antigen has slightly lower mobility in
SDS-PAGE than the nonreduced monomer [13—18]. Based on
those studies it would appear that the reduced 28 kD of rat and
human GMB reacting with rat autoantibody in our studies most
likely is the monomer of Goodpasture antigen. The nature of the
reduced 53 to 58 kD rat autoantibody reactive polypeptides is
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not clear. It is possible that they represent the nonreducible 52
to 54 kD polypeptides earlier observed by Butkowski et al [15].
Since we noted both the rat and Goodpasture autoantibodies to
react with similar nonreduced rat and human monomers and
dimers our results show that the rat autoantibody in this model
contains a population of autoantibodies which is similar to the
Goodpasture autoantibody. It is interesting to note that while
Goodpasture autoantibodies react only with the nonreduced
monomer the rat autoantibodies seem to react with both the
nonreduced and reduced forms. This suggest that the rat
autoantibodies contain populations of antibodies both against
the conformational and sequence types of epitopes of the
Goodpasture antigen.
Type IV collagen showed minimal reactivity in ELISA and
no reactive polypeptides were seen by Western blot analysis.
This may have been due to less sensitivity of Western blot
analysis over ELISA or due to partial denaturation of type IV
collagen during the former procedure.
Biochemical identity of the reactive soluble proteins of renal
cortex homogenate is only partially answered by our study.
Since no inhibition with Fx lB was seen on laminin and type IV
collagen coated plates, clearly the reactivity in the soluble
proteins was not due to laminin or type IV collagen. Although
the inhibition ELISA data showed that there were cross reac-
tive epitopes between the soluble proteins and the collagenase-
resistant noncollagenous portion of GBM, the Western blot
analyses of the two preparations did not identify a common
polypeptide. Therefore, it appears that the soluble cortex
proteins do not contain the noncollagenous hexameric (globu-
lar) portion of type IV collagen or the Goodpasture-like antigen.
In summary, the data suggest that the reactive polypeptides in
the soluble proteins are not from laminin, type IV collagen,
noncollagenous portion to type IV collagen or the Goodpasture-
like antigen. Of the five to six polypeptides identified in the
soluble proteins, the 31 kD polypeptide seems to be most
dominant. However, what is the identity of the parent macro-
molecule to which this 31 kD and the other polypeptides belong
has not been answered.
It is of interest to compare the renal reactivity of our rat
monoclonal antibody against B subunit to similar (B subunit)
monoclonal antibodies described by other investigators. Chung
et al [30] and Jaffe et al [31] obtained two rat monoclonal
antibodies to mouse laminin B subunit. One of these reacted in
a linear pattern with all tubular basement membranes, GBM
and glomerular mesangium but not with blood vessel wall. The
other reacted with only some tubular basement membranes,
some parts of glomerular mesangium but did not react with
GEM. Engvall et al [32] prepared a mouse monoclonal to
human laminin B subunit but did not describe its renal his-
tologic reactivity. Our antibody reacts with GBM or the adja-
cent plasma membrane of viseral glomerular epithelial cell and
with vessel wall but does not react with tubular basement
membrane or the glomerular mesangium. These differences in
reactivity are probably due to differences in the configuration of
the various epitopes in B subunit.
In summary, we have confirmed the recent ELISA results of
Fukatsu et al who showed that the in vivo bound antibodies
reacted strongly with laminin and weakly with type IV collagen.
In addition, we have shown that: 1) in laminin the reactive
epitopes are localized in the B subunit and absent on A subunit;
2) the reactive epitopes are also present in collagenase-resistant
noncollagenous portion of GBM; 3) the pattern of reactive
epitopes detected by Goodpasture autoantibody and rat auto-
antibody on human and rat GBM were similar showing that
some of the rat autoantibodies are directed against epitopes in
GBM which is the rat equivalent of Goodpasture antigen; 4) the
autoantibodies directed against the rat equivalent of Goodpas-
ture antigen appear to contain antibodies that react with both
the conformational and sequence type epitopes; 5) the reactive
epitopes are present on saline soluble proteins of kidney cortex
homogenate with the dominant of these proteins being a 31 kD
polypeptide; 6) the reactive epitopes in the soluble proteins are
not due to laminin and type IV collagen; and 7) that there are
shared epitopes between the reactive soluble proteins and the
collagenase-resistant noncollagenous portion of GBM.
HgCl2 induced anti-GBM autoantibodies are a model for the
drug induced autoimmunity. Data presented here have identi-
fied the molecular forms of some of the putative antigens. This
knowledge may assist in future studies in the understanding of
the mechanisms of damage in this toxin-induced autoimmune
disease and perhaps toxin induced autoimmunity in general.
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